N⁴-(5'-adenosyl)-N⁴-methyl-2-(R,S),4-diaminobutanoic acid | 129828-73-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: N⁴-(5'-adenosyl)-N⁴-methyl-2-(R,S),4-diaminobutanoic acid
• 英文别名: 2-amino-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylamino]butanoic acid
• CAS: 129828-73-5
• 化学式: C₁₅H₂₃N₇O₅
• 分子量: 381.392
• InChiKey: JISVTSUBJCPLSV-HVMNINKTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  186
• 氢给体数：
  5
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  5-脱氧-5-(甲基氨基)-2,3-O-(1-甲基亚乙基)-腺苷酸 在 硫酸 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 342.0h， 生成 N⁴-(5'-adenosyl)-N⁴-methyl-2-(R,S),4-diaminobutanoic acid
  参考文献：
  名称：

  General synthetic approach to stable nitrogen analogs of S-adenosylmethionine

  摘要：

  DOI：

  10.1021/jo00256a010

文献信息

• Markers for melanoma
  申请人：UNIVERSITY COLLEGE DUBLIN

  公开号：EP1840227A1

  公开（公告）日：2007-10-03

  A method of diagnosing melanoma and/or monitoring melanoma progression, in particular for determining whether the melanoma is likely to have metastatic capabilities, in a subject includes the steps of in a test sample determining the methylation status of FABP5 wherein methylation of the gene indicates a positive diagnosis of melanoma and/or increased methylation of the gene indicates the progression of melanoma. Methods of monitoring melanoma progesssion may also incorporate measuring the expression levels of FABP5, with low levels of expression indicating a positive diagnosis of melanoma and/or lower levels of expression being indicative of progression of melanoma. Methods of treating melanoma in a subject comprise administering a therapeutically effective amount of a DNA methyltransferase inhibitor or a histone deacetylase inhibitor to the subject such that expression of FABP5 is increased. Microarrays for use in these diagnostic methods and compound screening methods based around monitoring methylation and/or expression of FABP5 are also envisaged.

  一种诊断黑色素瘤和/或监测黑色素瘤进展的方法，特别是用于确定黑色素瘤是否可能具有转移能力的方法，包括以下步骤：在检测样本中确定 FABP5 的甲基化状态，其中基因的甲基化表明黑色素瘤诊断阳性和/或基因的甲基化增加表明黑色素瘤进展。监测黑色素瘤进展的方法还可包括测量 FABP5 的表达水平，表达水平低表明黑色素瘤诊断阳性和/或表达水平低表明黑色素瘤进展。治疗受试者黑色素瘤的方法包括向受试者施用治疗有效量的 DNA 甲基转移酶抑制剂或组蛋白去乙酰化酶抑制剂，从而提高 FABP5 的表达。还设想了用于这些诊断方法和化合物筛选方法的微阵列，其基础是监测FABP5的甲基化和/或表达。
• Epigenetic change in selected genes and cancer
  申请人：MDxHealth SA

  公开号：EP2650377A1

  公开（公告）日：2013-10-16

  A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.

  一种检测样本中癌症易感性或发病率的方法包括检测至少一种基因的表观遗传变化，这些基因选自 NDRG4/NDRG2 亚家族基因、GATA4、OSMR、GATA5、SFRP1、ADAM23、JPH3、SFRP2、APC、MGMT、TFPI2、BNIP3、FOXE1、SYNE1、SOX17、PHACTR3 和 JAM3 中的至少一个基因的表观遗传变化，其中检测到的表观遗传变化表明癌症的易感性或发病率。本发明还描述了用于确定合适的癌症治疗方案的药物遗传学方法，以及根据本发明方法选择患者治疗癌症患者的方法。本发明还涉及收集、处理和分析样本，特别是体液样本的改进方法。这些方法可用于诊断、分期或以其他方式表征各种疾病。本发明还涉及对癌症，特别是胃肠道癌症（如结肠直肠癌、胃癌和食道癌）进行鉴定、诊断、分期或表征的方法。本发明的方法主要涉及从粪便样本和血液样本中分离和分析人类 DNA 成分。
• Methylation detection of the MGMT promoter
  申请人：MDxHealth SA

  公开号：US10053724B2

  公开（公告）日：2018-08-21

  A real-time method of detecting the presence and/or amount of a methylated or unmethylated gene of interest in a DNA-containing sample, comprises the steps of: (a) contacting the DNA-containing sample with a reagent which selectively modifies unmethylated cytosine residues in the DNA to produce detectable modified residues but which does not modify methylated cytosine residues (b) amplifying at least a portion of the methylated or unmethylated gene of interest using at least one primer pair, at least one primer of which is designed to bind only to the sequence of methylated or unmethylated DNA following treatment with the reagent, wherein at least one primer in the primer pair produces a detectable fluorescence signal during amplification which is detected in real-time (c) quantifying the results of the real-time detection against a standard curve for the methylated or unmethylated gene of interest to produce an output of gene copy number.

  一种实时检测含 DNA 样本中是否存在甲基化或未甲基化的相关基因和/或其数量的方 法，包括以下步骤(a) 将含 DNA 样品与一种试剂接触，该试剂可选择性地修饰 DNA 中未甲基化的胞嘧啶残基以产生可检测的修饰残基，但不修饰甲基化的胞嘧啶残基 (b) 使用至少一对引物扩增感兴趣的甲基化或未甲基化基因的至少一部分、(c) 根据甲基化或未甲基化基因的标准曲线对实时检测结果进行量化，以得出基因拷贝数。
• Methods for detecting epigenetic modifications
  申请人：Exact Sciences Development Company, LLC

  公开号：US10808286B2

  公开（公告）日：2020-10-20

  A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.

  一种检测样本中癌症易感性或发病率的方法包括检测至少一种基因的表观遗传变化，这些基因选自 NDRG4/NDRG2 亚家族基因、GATA4、OSMR、GATA5、SFRP1、ADAM23、JPH3、SFRP2、APC、MGMT、TFPI2、BNIP3、FOXE1、SYNE1、SOX17、PHACTR3 和 JAM3 中的至少一个基因的表观遗传变化，其中检测到的表观遗传变化表明癌症的易感性或发病率。本发明还描述了用于确定合适的癌症治疗方案的药物遗传学方法，以及根据本发明方法选择患者治疗癌症患者的方法。本发明还涉及收集、处理和分析样本，特别是体液样本的改进方法。这些方法可用于诊断、分期或以其他方式表征各种疾病。本发明还涉及对癌症，特别是胃肠道癌症（如结肠直肠癌、胃癌和食道癌）进行鉴定、诊断、分期或表征的方法。本发明的方法主要涉及从粪便样本和血液样本中分离和分析人类 DNA 成分。
• MINNICK, ALBERT A.;KENYON, GEORGE L., J. ORG. CHEM., 53,(1988) N 21, C. 4952-4961
  作者：MINNICK, ALBERT A.、KENYON, GEORGE L.

  DOI：——

  日期：——